t(6;11)(q15;q23) KMT2A/?
2009-03-01 Jong Rak Choi  , Tae Sung Park   Affiliation1.Department of Laboratory Medicine, Kyung Hee University College of Medicine, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-702, Korea (TSP); Department of Laboratory Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, Korea (JRC)
Clinics and Pathology
Disease
Note
Only 4 cases to date, 3 of which do not provide further descriptions.
Phenotype stem cell origin
All cases were acute myeloid leukaemia (AML); AML-M0 (1 case), AML-M2 (1 case), AML-M4 (2 cases).
Epidemiology
All patients were female between the ages of 13 to 68 years.

Multi-color FISH image showing t(6;11)(q15;q23).

Bone marrow morphology from AML-M2 case with t(6;11)(q15;q23).
Prognosis
Very poor in 1 case (survival : only 2 weeks in AML-M2).
Cytogenetics
Cytogenetics morphological
It shows distinct balanced chromosomal abnormalities between chromosomes 6 and 11; however, it should be differentiated from t(6;11)(q13;q23) in association with MLL/ SMAP1 rearrangement.
Cytogenetics molecular
MLL breakapart FISH probe is very useful.
Additional anomalies
del(5)(q13q15) in 1 case, sole abnormality in remaining 3 cases.
Genes Involved and Proteins
Note
The gene involved in 6q15 is unknown.
Gene name
KMT2A (myeloid/lymphoid or mixed lineage leukemia)
Location
11q23.3
Note
More than 50 different translocation fusion partners in association with the MLL gene have been reported in the literature. In chromosome 6, t(6;11)(q27;q23) (MLL/AF6 rearrangement) is the most commonly encountered chromosomal abnormality. In contrast, t(6;11)(q13;q23) or t(6;11)(q15;q23) is the rarest type of MLL rearrangement involving the long arm of chromosome 6.
Result of the Chromosomal Anomaly
Note
Unknown. However, MLL/SMAP1 rearrangement was excluded in one case by both our group and Dr. Meyer.Unknown.
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 41350360 | 2025 | Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy. | 214 |
| 39887730 | 2026 | Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions. | 129 |
| 36979800 | 2023 | Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia. | 111 |
| 35328068 | 2022 | KMT2A: Umbrella Gene for Multiple Diseases. | 104 |
| 36635503 | 2023 | Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes. | 102 |
| 41192422 | 2025 | Disparate leukemia mutations converge on nuclear phase-separated condensates. | 98 |
| 39303915 | 2024 | Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation. | 94 |
| 39594699 | 2024 | Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions. | 94 |
| 40361241 | 2025 | Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies. | 86 |
| 39475509 | 2024 | NUP98 fusion proteins and KMT2A-MENIN antagonize PRC1.1 to drive gene expression in AML. | 83 |
| 38888967 | 2024 | KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenoma. | 83 |
| 40956618 | 2025 | In utero rescue of neurological dysfunction in a mouse model of Wiedemann-Steiner syndrome. | 83 |
| 40501735 | 2025 | Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia. | 83 |
| 37788669 | 2023 | Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement. | 81 |
| 38889007 | 2024 | An enhancer RNA recruits KMT2A to regulate transcription of Myb. | 80 |
| 41279818 | 2025 | ZMYND11 Restrains KMT2A to Enable a Neuronal Developmental Program. | 80 |
| 38612531 | 2024 | Infant Acute Lymphoblastic Leukemia-New Therapeutic Opportunities. | 79 |
| 37019990 | 2023 | The KMT2A recombinome of acute leukemias in 2023. | 76 |
| 41062506 | 2025 | The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia. | 74 |
| 41749890 | 2026 | Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care. | 74 |
| 37891368 | 2023 | SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML. | 74 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 36781850 | 2023 | Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia. | 68 |
| 39380002 | 2024 | The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency. | 68 |
| 36629017 | 2023 | DNA fragility at the KMT2A/MLL locus: insights from old and new technologies. | 67 |
| 39682203 | 2024 | Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor. | 62 |
| 37709746 | 2023 | KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. | 61 |
| 39201709 | 2024 | KMT2A Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives. | 60 |
| 37036970 | 2023 | Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. | 60 |
| 33542482 | 2021 | Menin is necessary for long term maintenance of meningioma-1 driven leukemia. | 58 |
| 39572532 | 2024 | KMT2A regulates the autophagy-GATA4 axis through METTL3-mediated m(6)A modification of ATG4a to promote NPCs senescence and IVDD progression. | 57 |
| 34663924 | 2021 | Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia. | 57 |
| 36479909 | 2023 | KMT2A-D pathogenicity, prevalence, and variation according to a population database. | 57 |
| 36181613 | 2022 | Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A. | 57 |
| 37100882 | 2023 | The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome. | 57 |
| 40729681 | 2025 | Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients. | 55 |
| 40646135 | 2025 | Ontogeny-specific induction of the KMT2A::AFF1-fusion drives development of a distinct CD24 positive pre-leukemic state. | 55 |
| 39704147 | 2025 | Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia. | 50 |
| 34864916 | 2022 | Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. | 49 |
| 38049829 | 2023 | Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. | 49 |
| 34550633 | 2022 | KMT2A-MAML2 rearrangement emerged and regressed during neuroblastoma therapy without leukemia after 12.8-year follow-up. | 49 |
| 39888275 | 2025 | Histone methyltransferase KMT2A promotes pulmonary fibrogenesis via targeting pro-fibrotic factor PU.1 in fibroblasts. | 46 |
| 32436862 | 2020 | KMT2A regulates cervical cancer cell growth through targeting VDAC1. | 45 |
| 40672274 | 2025 | Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy. | 44 |
| 34048275 | 2021 | Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. | 43 |
| 38905635 | 2024 | Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. | 40 |
| 39086307 | 2024 | Revumenib for patients with acute leukemia: a new tool for differentiation therapy. | 40 |
| 38025523 | 2023 | KMT2A maintains stemness of gastric cancer cells through regulating Wnt/β-catenin signaling-activated transcriptional factor KLF11. | 40 |
| 41849234 | 2026 | Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models. | 39 |
| 36213638 | 2022 | Clinical profile in KMT2A-SEPT6-positive acute myeloid leukemia: Does it often co-occur with NRAS mutations? | 37 |
| 38621200 | 2024 | Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. | 35 |
| 24291127 | 2014 | Diverse functions of PHD fingers of the MLL/KMT2 subfamily. | 33 |
| 39766092 | 2024 | Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes. | 33 |
| 36922593 | 2023 | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. | 31 |
| 37649104 | 2023 | A de novo mutation of ADAMTS8 in a patient with Wiedemann-Steiner syndrome. | 27 |
| 37813299 | 2023 | Droplet Digital PCR for Oncogenic KMT2A Fusion Detection. | 26 |
| 31592798 | 2020 | Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma. | 25 |
| 40879254 | 2025 | YAP1::KMT2A-Rearranged Sarcoma: Report of a New Case With Unusual Morphology and Immunohistochemical Features. | 22 |
| 32611575 | 2020 | NUP98 and KMT2A: usually the bride rather than the bridesmaid. | 21 |
| 36352192 | 2023 | Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma. | 14 |
| 35584376 | 2022 | Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. | 13 |
| 39264614 | 2024 | A menin-KMT2A inhibitor to overcome resistance. | 10 |
| 41121446 | 2025 | KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes. | 10 |
| 39280986 | 2024 | Pitfalls in Diagnosis: JMML versus KMT2A Rearranged Juvenile AML. | 10 |
| 34148065 | 2021 | Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia. | 10 |
| 40501411 | 2025 | Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia. | 9 |
| 36395313 | 2022 | Infant Leukemia. | 0 |
| 37995105 | 2023 | Unraveling KMT2A-rearranged ALL. | 0 |
| 36301633 | 2022 | KMT2A-rearranged leukemia: the shapeshifter. | 0 |
| 41653248 | 2026 | Ziftomenib: First Approval. | 0 |
| 40072775 | 2025 | Revumenib: First Approval. | 0 |
| 36991259 | 2023 | Menin-KMT2A interaction inhibitor shows promise. | 0 |
| 40441466 | 2025 | Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy. | 0 |
| 36964033 | 2023 | KMT2A amplification in B lymphoblastic leukaemia. | 0 |
| 35716019 | 2022 | Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. | 0 |
| 41231456 | 2025 | Mantle cell lymphoma with KMT2A rearrangement. | 0 |
| 41144759 | 2026 | Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML. | 0 |
| 41033852 | 2025 | Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts. | 0 |
| 37712389 | 2024 | A novel KMT2A::DCP1B rearrangement in chronic neutrophilic leukemia. | 0 |
| 40768751 | 2025 | Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML. | 0 |
| 37575084 | 2023 | VIM::KMT2A rearranged sarcoma: a rare emerging entity. | 0 |
| 33314053 | 2021 | Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia. | 0 |
| 38234854 | 2024 | KMT2A oncoproteins induce epigenetic resistance to targeted therapies. | 0 |
| 36930260 | 2023 | Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma. | 0 |
| 30707474 | 2019 | Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory. | 0 |
| 35933946 | 2022 | KMT2A-CBL fusion in rapidly progressive myeloid disorder. | 0 |
| 38710595 | 2024 | The Menin story in acute myeloid leukaemia-The road to success. | 0 |
| 40749582 | 2025 | Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies. | 0 |
| 36441356 | 2023 | Evolution and optimization of therapies for acute lymphoblastic leukemia in infants. | 0 |
| 38955714 | 2024 | [YAP1-KMT2A fused sarcoma: report of a case]. | 0 |
| 37248168 | 2023 | Acute monocytic leukemia with KMT2A:MLLT10 transformed to AML-M7 in a pediatric patient. | 0 |
| 25131304 | 2015 | MLL/KMT2A translocations in diffuse large B-cell lymphomas. | 0 |
| 34324764 | 2022 | Acute lymphoblastic leukemia in infants: A quarter century of nationwide efforts in Japan. | 0 |
| 39579612 | 2025 | Ailanthone targets the KMT2A-MEN1 complex to suppress lung metastasis of osteosarcoma. | 0 |
| 42318777 | 2026 | KMT2A and KMT2B episignatures address diagnostic challenges associated with rare neurodevelopmental disorders. | 0 |
| 28723559 | 2017 | KMT2A and KMT2B Mediate Memory Function by Affecting Distinct Genomic Regions. | 0 |
| 38520957 | 2024 | Raman spectroscopy can recognize the KMT2A rearrangement as a distinct subtype of leukemia. | 0 |
| 40944346 | 2025 | LDB1::KMT2A Fusion in a Spindle-Cell Sarcoma: A Case Report. | 0 |
| 31710778 | 2020 | Wiedemann-Steiner syndrome in two patients from Portugal. | 0 |
| 25284327 | 2015 | The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 15626757 | 2005 | Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. | Meyer C et al |
| 18983303 | 2008 | Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. | Park JS et al |
| 18992643 | 2008 | MLL rearrangement with t(6;11)(q15;q23) as a sole abnormality in a patient with de novo acute myeloid leukemia: conventional cytogenetics, FISH, and multicolor FISH analyses for detection of rare MLL-related chromosome abnormalities. | Park TS et al |
| 15921375 | 2005 | Analysis of balanced rearrangements of chromosome 6 in acute leukemia: clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new recurrent translocation, t(6;7)(q23;q32 through 36). | Sinclair P et al |
| 8123853 | 1994 | Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). | Stasi R et al |
Summary

Giemsa-banding partial karyograms of t(6;11)(q15;q23). (Each left side chromosomes 6 and 11: normal, each right side chromosomes 6 and 11: derivative chromosome).
Citation
Jong Rak Choi ; Tae Sung Park
t(6;11)(q15;q23) KMT2A/?
Atlas Genet Cytogenet Oncol Haematol. 2009-03-01
Online version: http://atlasgeneticsoncology.org/haematological/1522/t(6
